Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678318 | 0.97 | CA1 (0.33) | CA1CA12CA7CA14CA2 | |
| SCHEMBL19829588 | 0.83 | — | — | |
| SCHEMBL2289605 | 0.77 | CA1 (0.35) | CA1CA12CA7CA14CA2 | |
| SCHEMBL3178430 | 0.75 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL3187913 | 0.75 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL433101 | 0.75 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL24629023 | 0.73 | CA1 (0.41) | CA1CA12CA7CA14CA2 | |
| SCHEMBL547762 | 0.73 | CA1 (0.41) | CA1CA12CA7CA14CA2 | |
| SCHEMBL3155782 | 0.73 | CA1 (0.41) | CA1CA12CA7CA14CA2 | |
| SCHEMBL11889594 | 0.73 | CA1 (0.41) | CA1CA12CA7CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971603-B1 | SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS | CADILA HEALTHCARE LTD (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20100240709-A1 | Sulfoximine Derivatives as p38 MAP Kinase Inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2010-09-23 | — | — | US | disclosed |
| EP-1971603-A2 | SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077574-A2 | SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240709-A1 | Sulfoximine Derivatives as p38 MAP Kinase Inhibitors | MAPK1, MAP3K11, MAP3K1 | CA1 3849/4885CA12 4383/4885CA7 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.